This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Prolintane: Difference between revisions
>Unity No edit summary |
>Kenan mNo edit summary |
||
| Line 8: | Line 8: | ||
'''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''' or '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities. | '''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''' or '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities. | ||
Historical reports show records of the preparation of prolintane for use as a mild CNS stimulant, wakefulness agent, and [[cocaine]]-cessation aid. It has been marketed in Europe since the 1960s as an antidepressant (i.e. | Historical reports show records of the preparation of prolintane for use as a mild CNS stimulant, wakefulness agent, and [[cocaine]]-cessation aid. It has been marketed in Europe since the 1960s as an antidepressant (i.e. anti-fatigue properties) and analeptic. It has a history of being used in neuropsychiatric research related to CNS stimulants with reduced side effects. Therapeutic uses of prolintane in Africa, Europe, and Australia include the treatment of narcolepsy, ADHD, fatigue and orthostatic hypotension. It is not approved for pharmaceutic use in the United States.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref> | ||
The first reports of prolintane abuse appeared in Europe during the early 200s when prolintane was identified in tablets distributed at a rave party. Later reports documented the recreational use of prolintane in the United States, where it appears to substitute for amphetamines.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref> | The first reports of prolintane abuse appeared in Europe during the early 200s when prolintane was identified in tablets distributed at a rave party. Later reports documented the recreational use of prolintane in the United States, where it appears to substitute for amphetamines.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref> | ||
| Line 76: | Line 76: | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
The toxicity and long-term health effects of recreational prolintane use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. Anecdotal evidence from people who have tried prolintane within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | The toxicity and long-term health effects of recreational prolintane use do not seem to have been studied in any scientific context, and the exact toxic dosage is unknown. Anecdotal evidence from people who have tried prolintane within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | ||
===Lethal dosage=== | ===Lethal dosage=== | ||
The exact lethal dosage of prolintane is unknown and no formal studies have been carried out in humans. The typical adult therapeutic dose of prolintane has been 10-40mg daily. In therapeutic trials, 20mg prolintant is a mild stimulant equivalent to 100mg caffeine. In a study of fatigued volunteers the administration of 20mg or 40mg prolintane produced similar, but less intense effects than 20mg [[amphetamine|d-amphetamine]]. In experimental studies of healthy volunteers, prolintane has little cardiovascular activity following the single dose of 20mg.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref> | The exact lethal dosage of prolintane is unknown, and no formal studies have been carried out in humans. The typical adult therapeutic dose of prolintane has been 10-40mg daily. In therapeutic trials, 20mg prolintant is a mild stimulant equivalent to 100mg caffeine. In a study of fatigued volunteers the administration of 20mg or 40mg prolintane produced similar, but less intense effects than 20mg [[amphetamine|d-amphetamine]]. In experimental studies of healthy volunteers, prolintane has little cardiovascular activity following the single dose of 20mg.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref> | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||